Expression of p53, MDM2, p21, heat shock protein 70, and HPV 16/18 E6 proteins in oral verrucous carcinoma and oral verrucous hyperplasia

Head and Neck

Volumn 33, Issue 3, 2011, Pages 334-340

  Lin, Hung Pin ^a   Wang, Yi Ping ^a   Chiang, Chun Pin ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

heat shock protein 70; MDM2; p21; p53; verrucous carcinoma; verrucous hyperplasia

Indexed keywords

HEAT SHOCK PROTEIN 70; PROTEIN E6; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; EPITHELIOID CELL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; ORAL VERRUCOUS CARCINOMA; ORAL VERRUCOUS HYPERPLASIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VERRUCOUS CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, VERRUCOUS; CHILD; COHORT STUDIES; DNA, VIRAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP70 HEAT-SHOCK PROTEINS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH DISEASES; MOUTH NEOPLASMS; P21-ACTIVATED KINASES; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS C-MDM2; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 79951705384     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21452     Document Type: Article

References (33)

1. Ackerman LV,. Verrucous carcinoma of the oral cavity. Surgery 1948; 23: 670-678.
2. Shear M, Pindborg JJ,. Verrucous hyperplasia of the oral mucosa. Cancer 1980; 46: 1855-1862. (Pubitemid 10011143)
3. Regezi JA, Zarbo RJ, Regev E, Pisanty S, Silverman S, Gazit D,. p53 protein expression in sequential biopsies of oral dysplasias and in situ carcinomas. J Oral Pathol Med 1995; 24: 18-22.
4. Chiang CP, Huang JS, Wang JT, et al. Expression of p53 protein correlates with decreased survival in patients with areca quid chewing and smoking-associated oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 1999; 28: 72-76.
5. Kuo MY, Huang JS, Hsu HC, et al. Infrequent p53 mutations in patients with areca quid chewing-associated oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 1999; 28: 221-225. (Pubitemid 29188410)
6. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B,. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-860. (Pubitemid 23132165)
7. Honda R, Tanaka H, Yasuda H,. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420: 25-27. (Pubitemid 28037193)
8. Hubbert NL, Sedman SA, Schiller JT,. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol 1992; 66: 6237-6241.
9. Yugawa T, Kiyono T,. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol 2009; 19: 97-113.
10. Finaly CA, Hinds PW, Tan PH, Eliyahu D, Oren M, Levine AJ,. Activating mutations for transformation by p53 produce a gene product that forms an hsc-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531-539.
11. Wadhwa R, Takano S, Mitsui Y, Kaul SC,. NIH 3T3 cells malignantly transformed by mot-2 show inactivation and cytoplasmic sequestration of the p53 protein. Cell Res 1999; 9: 261-269. (Pubitemid 129623931)
12. Abbas T, Dutta A,. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400-414.
13. Koch BB, Trask DK, Hoffman HT, et al. National survey of head and neck verrucous carcinoma: patterns of presentation, care, and outcome. Cancer 2001; 92: 110-120. (Pubitemid 32623047)
14. Chang KC, Su IJ, Tsai ST, Shieh DB, Jin YT,. Pathological features of betel quid-related oral epithelial lesions in Taiwan with special emphasis on the tumor progression and human papillomavirus association. Oncology 2002; 63: 362-369.
15. Slootweg PJ, Muller H,. Verrucous hyperplasia or verrucous carcinoma. An analysis of 27 patients. J Maxillofac Surg 1983; 11: 13-19. (Pubitemid 13124828)
16. Noel JC, Peny MO, De Dobbeleer G, et al. p53 Protein overexpression in verrucous carcinoma of the skin. Dermatology 1996; 192: 12-15. (Pubitemid 26026786)
17. Adegboyega PA, Boromound N, Freeman DH,. Diagnostic utility of cell cycle and apoptosis regulatory proteins in verrucous squamous carcinoma. Appl Immunohistochem Mol Morphol 2005; 13: 171-177. (Pubitemid 40726855)
18. Lam KY, Chan AC, Chan KW, Leung ML, Srivastava G,. Expression of p53 and its relationship with human papillomavirus in penile carcinomas. Eur J Surg Oncol 1995; 21: 613-616. (Pubitemid 26042308)
19. Stankiewicz E, Kudahetti SC, Prowse DM, et al. HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis. Mod Pathol 2009; 22: 1160-1168.
20. Noel JC, Vandenbossche M, Peny MO, et al. Verrucous carcinoma of the penis: importance of human papillomavirus typing for diagnosis and therapeutic decision. Eur Urol 1992; 22: 83-85.
21. Lopez-Amado M, Garcia-Caballero T, Lozano-Ramirez A, Labella-Caballero T,. Human papillomavirus and p53 oncoprotein in verrucous carcinoma of the larynx. J Laryngol Otol 1996; 110: 742-747. (Pubitemid 26334973)
22. Gimenez-Conti IB, Collet AM, Lanfranchi H, et al. p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas. Cancer 1996; 78: 17-23. (Pubitemid 26189899)
23. Wu M, Putti TC, Bhuiya TA,. Comparative study in the expression of p53, EGFR, TGF-alpha, and cyclin D1 in verrucous carcinoma, verrucous hyperplasia, and squamous cell carcinoma of head and neck region. Appl Immunohistochem Mol Morphol 2002; 10: 351-356. (Pubitemid 35453695)
24. Ogawa A, Fukuta Y, Nakajima T, et al. Treatment results of oral verrucous carcinoma and its biological behavior. Oral Oncol 2004; 40: 793-797. (Pubitemid 39061094)
25. Benjamin H, Klieb E, Raphael SJ,. Comparative study of the expression of p53, Ki67, E-cadherin and MMP-1 in verrucous hyperplasia and verrucous carcinoma of the oral cavity. Head Neck Pathol 2007; 1: 118-122.
26. Ouban A, Dellis J, Salup R, Morgan M,. Immunohistochemical expression of Mdm2 and p53 in penile verrucous carcinoma. Ann Clin Lab Sci 2003; 33: 101-106. (Pubitemid 36337006)
27. Bouska A, Eischen CM,. Murine double minute 2: p53-independent roads lead to genome instability or death. Trends Biochem Sci 2009; 34: 279-286.
28. Lam KY, Chan KW,. Molecular pathology and clinicopathologic features of penile tumors: with special reference to analyses of p21 and p53 expression and unusual histologic features. Arch Pathol Lab Med 1999; 123: 895-904. (Pubitemid 29480448)
29. Garrido C, Brunet M, Didelot D, Zermati Y, Schmitt E, Kroemer G,. Heat shock proteins 27 and 70: antiapoptotic proteins with tumorigenic properties. Cell Cycle 2006; 22: 2592-2601. (Pubitemid 44785803)
30. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, Thomas SJ,. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 2006; 31: 259-266. (Pubitemid 44141088)
31. Poh CF, Zhang L, Lam WL, et al. A high frequency of allelic loss in oral verrucous lesions may explain malignant risk. Lab Invest 2001; 81: 629-634. (Pubitemid 32298808)
32. Yu CH, Chen HM, Hung HY, Cheng SJ, Tsai T, Chiang CP,. Photodynamic therapy outcome for oral verrucous hyperplasia depends on the clinical appearance, size, color, epithelial dysplasia, and surface keratin thickness of the lesion. Oral Oncol 2008; 44: 595-600.
33. Chen HM, Chen CT, Yang H, et al. Successful treatment of an extensive verrucous carcinoma with topical 5-aminolevulinic acid-mediated photodynamic therapy. J Oral Pathol Med 2005; 34: 253-256. (Pubitemid 40445160)